PIR International’s EU/UK Biotech C-Suite Remuneration & Diversity Study is a data-driven resource that empowers executives, investors and the boardroom with the insights they need to improve board governance, top-level business decisions and truly excel. This strictly independent, anonymised and confidential remuneration study is designed to leverage participation from the entire European and UK biotech ecosystem that will give the very latest data to drive important insights for all decision-makers in the sector.
Available 28th February 2024, PIR International’s EU/UK Biotech C-Suite Remuneration & Diversity Study dissects remuneration, participation, equity level, geographic and diversity representation, in correlation to key metrics such as investment level, founder status and other quantitative and qualitative measures. All aimed to give the latest and actionable insights for company governance in the European and UK biotech sector.
2024 C-Suite Study Results Registration Form
"*" indicates required fields